Solara Active Pharma Sciences (NSE:SOLARA) Is Growing Earnings But Are They A Good Guide?

It might be old fashioned, but we really like to invest in companies that make a profit, each and every year. Having said that, sometimes statutory profit levels are not a good guide to ongoing profitability, because some short term one-off factor has impacted profit levels. Today we'll focus on whether this year's statutory profits are a good guide to understanding Solara Active Pharma Sciences (NSE:SOLARA).

While Solara Active Pharma Sciences was able to generate revenue of ₹13.9b in the last twelve months, we think its profit result of ₹1.58b was more important. The chart below shows that revenue has been pretty flat over the last three years, but profit has increased.

See our latest analysis for Solara Active Pharma Sciences

Of course, when it comes to statutory profit, the devil is often in the detail, and we can get a better sense for a company by diving deeper into the financial statements. In this article we'll look at how Solara Active Pharma Sciences is impacting shareholders by issuing new shares. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

In order to understand the potential for per share returns, it is essential to consider how much a company is diluting shareholders. In fact, Solara Active Pharma Sciences increased the number of shares on issue by 38% over the last twelve months by issuing new shares. Therefore, each share now receives a smaller portion of profit. To talk about net income, without noticing earnings per share, is to be distracted by the big numbers while ignoring the smaller numbers that talk to per share value. You can see a chart of Solara Active Pharma Sciences' EPS by clicking here.

A Look At The Impact Of Solara Active Pharma Sciences' Dilution on Its Earnings Per Share (EPS).

As you can see above, Solara Active Pharma Sciences has been growing its net income over the last few years, with an annualized gain of 5,156% over three years. But EPS was only up per year, in the exact same period. And at a glance the 52% gain in profit over the last year impresses. But in comparison, EPS only increased by 41% over the same period. Therefore, one can observe that the dilution is having a fairly profound effect on shareholder returns.

Changes in the share price do tend to reflect changes in earnings per share, in the long run. So Solara Active Pharma Sciences shareholders will want to see that EPS figure continue to increase. But on the other hand, we'd be far less excited to learn profit (but not EPS) was improving. For the ordinary retail shareholder, EPS is a great measure to check your hypothetical "share" of the company's profit.

Our Take On Solara Active Pharma Sciences' Profit Performance

As we discussed above, Solara Active Pharma Sciences' dilution over the last year has a major impact on its per-share earnings. For this reason, we think that Solara Active Pharma Sciences' statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. The good news is that, its earnings per share increased by 41% in the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. So while earnings quality is important, it's equally important to consider the risks facing Solara Active Pharma Sciences at this point in time. To help with this, we've discovered 3 warning signs (1 makes us a bit uncomfortable!) that you ought to be aware of before buying any shares in Solara Active Pharma Sciences.

This note has only looked at a single factor that sheds light on the nature of Solara Active Pharma Sciences' profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

If you decide to trade Solara Active Pharma Sciences, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account. Promoted

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
^*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.